Johns Hopkins Medicine researchers have shown that people 60 years or older with weakened immunity -; primarily organ transplant recipients who take immunosuppressive medications to reduce the risk of ...
Researchers have shown that people 60 years or older with weakened immunity do not respond as strongly to vaccines against the respiratory syncytial virus (RSV) as people in the same age group with ...
Cardinalizumab (Ketanil) is a bi-specific antibody acts as programmed death 1 protein (PD-1) antagonist and CTLA4 antagonist. It is formulated as solution for inravenous route of administration.
Scanning electron micrograph of human respiratory syncytial virus (RSV) virions (colorized blue) and tagged with antibodies (colorized yellow) against the virus’ fusion protein — the target of RSV ...
The company’s pipeline products include KN035; an injectable PD-L1 inhibitor for the treatment of dMMR and MSI-H solid tumors, KN046; a BsAb immune checkpoint inhibitor, KN026; an anti-HER2 bispecific ...